ProQR Therapeutics N.V. Ordinary Shares (PRQR)
ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic eye diseases and other rare genetic disorders. Founded in 2012 and based in the Netherlands, it specializes in designing therapies that target the root causes of these conditions, aiming to provide transformative treatments for patients with limited options.
Company News
ProQR Therapeutics received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects for a Phase 1 study of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases. The company will host a virtual investor event on November 3, 2025 to discuss the clinica...
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents. KeyCorp shares fell 5.4% to $13.10 on Thursday. Here are some o...
The clinical-stage biotech released fourth-quarter and full-year earnings.
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.